BioSpace News Archive

Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease, announced that Andres Bratt-Leal, PhD, has been promoted to Senior Vice President of Research & Development.

New agreement sees Isohelix GeneFix™ Saliva DNA and RNA Collection Devices integrated into AutoGen FlexSTAR DNA extraction workflows

Accelerate Diagnostics, Inc. announced that management will host a conference call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time to review 2021 first quarter financial results.

Nucleus Research, an independent research firm providing ROI-focused technology research services to both vendors and consumers, has published its Q2 2021 Equity Snapshot for human capital management solutions provider Ceridian.

Northwest Specialty is one of only three hospitals in the nation to feature two robots utilizing a state-of-the-art surgical robotic navigation system called the Excelsius GPS®.

Locanabio, Inc., an RNA-targeting gene therapy company focused on developing life-changing therapies for patients with severe neurodegenerative, neuromuscular and retinal diseases, announced that new data from its preclinical research will be highlighted in oral and poster presentations at the 24th Annual American Society of Gene and Cell Therapy Meeting, taking place virtually from May 11-14, 2021.

Scientific Data Unveiled at the 2021 ARVO Annual Meeting Benchmarks Real-World Endpoints Versus Randomized Controlled Pivotal Trials

FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022

Paul J. Diaz, president and CEO of Myriad Genetics, Inc., a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Bank of America Securities 2021 Virtual Health Care Conference at 2:45 p.m. EDT on May 12, 2021.

Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting